{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53.1","upperLimit":"70.4","value":"62.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"}],"units":"Participants"}],"description":"Objective response (OR) was assessed for all treated patients by independent review as determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. OR included complete response (CR) and partial response (PR), where CR or PR must have been confirmed by a subsequent response in ≥28 days.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients in the four initial cohorts are combined in the efficacy presentations. Patients start once daily oral treatment of BIBW 2992 (Afatinib) at 50 mg before protocol amendment 2 (17 Dec 2008), until progression or undue adverse events (AEs) development. Patients can be dose-reduced up to two times if needed after temporary interruption of treatment due to drug- related AEs. After protocol amendment 2, the starting dose of BIBW 2992 was reduced to 40 mg, with 2 possible dose reductions if needed after temporary dose interruption due to drug-related AEs.","id":"OG000","title":"Afatinib"}],"paramType":"NUMBER","populationDescription":"Treated set: The patients who had taken at least one dose of afatinib were included in the treated set.","reportingStatus":"POSTED","timeFrame":"Response assessment is done at end of Week 4 (after Course 1), Week 8 (after Course 2), Week 12 (after Course 3) and at 8-week intervals thereafter, up to 93 months.","title":"Objective Response (OR) as Determined by RECIST 1.0","type":"PRIMARY","unitOfMeasure":"percentage of participants"}